00364nas a2200085   4500000000100000008004100001245021500042300001400257490000700271       2019                            d00aA trial to evaluate the effect of the sodium–glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)  a665 - 6750 v21